Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2 Study of Pyrotinib Maleate in Advanced Solid Tumors Patients With HER2( Erb-B2 Receptor Tyrosine Kinase 2)-Postive

NCT04179656 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT04179656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2 Study of Pyrotinib Maleate in Advanced Solid Tumors Patients With HER2( Erb-B2 Receptor Tyrosine Kinase 2)-Postive
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2019
Completion date
December 31, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 gene amplification, her-2 protein overexpression, her2 gene mutation, solid tumor